Maryia Zhdanava
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.
Journal: Journal of managed care & specialty pharmacy
Published: June 24, 2026
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.
Journal: The Journal of dermatological treatment
Published: February 24, 2026
Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.
Journal: Neurology and therapy
Published: April 22, 2025
Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism.
Journal: Journal of managed care & specialty pharmacy
Published: March 28, 2025
Real-world prevalence of potential drug-drug interactions associated with oral advanced therapies indicated for ulcerative colitis.
Journal: Current medical research and opinion
Published: February 13, 2025
Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.
Journal: The Journal of clinical psychiatry
Published: February 03, 2025
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: December 20, 2024
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.
Journal: Drugs - real world outcomes
Published: December 17, 2024
Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab.
Journal: Current medical research and opinion
Published: August 06, 2024
Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.
Journal: Current medical research and opinion
Published: July 22, 2024
Health Care Resource Use and Medical Costs Among Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine Nasal Spray or Traditional Treatments in the United States.
Journal: Clinical therapeutics
Published: June 27, 2024
Treatment Persistence Among Anti-Tumor Necrosis Factor-experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti-Tumor Necrosis Factor Agent.
Journal: Clinical therapeutics
Published: June 26, 2024
Last Updated: 09/26/2026